Yüklüyor......
Avatrombopag, an oral thrombopoietin receptor agonist: results of two double‐blind, dose‐rising, placebo‐controlled Phase 1 studies
Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating thrombocytopenia in chronic liver disease patients needing invasive procedures. Clinical trials supporting this new treatment were guided by two double‐blind, dose‐rising, placebo‐controlled Phase 1...
Kaydedildi:
| Yayımlandı: | Br J Haematol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282597/ https://ncbi.nlm.nih.gov/pubmed/30203841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15574 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|